Eculizumab

Evidence Level: L5

Predicted Indications: 10

Eculizumab

Pharmacist Assessment Report

Eculizumab: From Paroxysmal Nocturnal Hemoglobinuria to Cyclic Hematopoiesis

One-Sentence Summary

Eculizumab is a complement C5 inhibitor, originally used to treat paroxysmal nocturnal hemoglobinuria and neuromyelitis optica. The TxGNN model predicts it may be effective for cyclic hematopoiesis (cyclic neutropenia), but there are 0 clinical trials and 0 publications that directly support this prediction. The prediction rests on the model score alone.

Quick Overview

Item	Content
Original Indication	Paroxysmal nocturnal hemoglobinuria; neuromyelitis optica (the Canadian licence text is not available)
Predicted New Indication	Cyclic hematopoiesis
TxGNN Prediction Score	0.9997
Evidence Level	L5
Canada Market Status	Marketed (marketed DINs: 1 of 1)
Number of DINs	1 (marketed: 1)
Recommended Decision	Hold

Why is This Prediction Reasonable?

Currently, detailed mechanism of action data is not available. Based on known information, eculizumab is a monoclonal antibody that blocks complement C5. It has proven efficacy in complement-mediated diseases such as paroxysmal nocturnal hemoglobinuria, and it is also used in conditions such as atypical hemolytic uremic syndrome and myasthenia gravis.

For cyclic hematopoiesis, however, no supporting mechanistic link has been identified. Cyclic neutropenia is typically caused by ELANE mutations, which make neutrophil production oscillate. It is not primarily a complement-mediated disease, so there is no clear rationale for C5 inhibition. The high score (0.9997) comes from the TxGNN model (deep learning) and may reflect similarities the model learned between related diseases, not biological evidence.

The other top-ranked predictions are also neutropenia or neutrophil-related disorders: severe congenital neutropenia and its genetic subtypes, adult idiopathic neutropenia, and primary immunodeficiency due to p14 deficiency. None of them has a complement-driven mechanism or any supporting trial or literature. Eculizumab also carries a risk of serious meningococcal infection, which is a particular concern in neutropenic or immunodeficient patients.

Clinical Trial Evidence

Currently no related clinical trials registered.

Literature Evidence

No publications address cyclic hematopoiesis. The literature retrieved for the fourth-ranked prediction (congenital neutropenia-myelofibrosis-nephromegaly syndrome) and the tenth-ranked prediction (primary release disorder of platelets) concerns eculizumab’s existing indications and does not support the predicted indication. Examples:

PMID	Year	Type	Journal	Key Findings
25237200	2014	Review	Blood	Reviews PNH, in which loss of CD55/CD59 causes uncontrolled complement activation and hemolysis
28622911	2017	Review	Molecular immunology	Neurological features of congenital CD59 mutations and the role of eculizumab
19556379	2009	Clinical report	Clin J Am Soc Nephrol	Eculizumab inhibits terminal complement in atypical hemolytic uremic syndrome
23271156	2012	Review	Clin Adv Hematol Oncol	Case-based roundtable on PNH; reflects the existing indication

Canada Market Information

DIN	Product Name	Dosage Form	Approved Indication
02322285	SOLIRIS	Not stated	Not stated

Safety Considerations

Drug Interactions: Four minor interactions were identified, all with human immunoglobulin G products (intravenous, subcutaneous, intramuscular, and combined intravenous and subcutaneous).

Please refer to the package insert for warnings and contraindications. Eculizumab is generally known to carry a risk of serious meningococcal infection, which should be checked against the Canadian label.

Conclusion and Next Steps

Decision: Hold

Rationale: The prediction has only a model score (0.9997), with no clinical trials or directly relevant publications, and no plausible complement-mediated mechanism in cyclic hematopoiesis. Infection risk with C5 inhibition is a further concern in neutropenic patients.

To proceed, the following is needed:

Evidence that complement activation contributes to the pathology of cyclic neutropenia
Mechanism of action data for the drug
Warnings and contraindications from the Health Canada package insert
Approved indication text and dosage form for the Canadian licence
Preclinical or case-level data, if any exist, before considering clinical studies
Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.